<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309605</url>
  </required_header>
  <id_info>
    <org_study_id>EL-002</org_study_id>
    <nct_id>NCT03309605</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of ELX-02 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eloxx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SGS Life Sciences, a division of SGS Belgium NV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eloxx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 Multiple Ascending Dose Study in Normal Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study in humans of ELX-02, an advanced synthetic aminoglycoside optimized as a&#xD;
      translational read-through drug (TRID) for the treatment of genetic conditions caused by&#xD;
      nonsense mutations. This is a classical Phase 1b study designed as a randomized,&#xD;
      double-blinded, placebo-controlled, multiple dose escalation to evaluate the safety,&#xD;
      tolerability, and pharmacokinetics of ELX-02 in healthy adult volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">June 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort 1: ELX-02 0.1 mg/kg or placebo SC twice a week for 9 doses;&#xD;
Cohort 2: ELX-02 0.3 mg/kg or placebo SC twice a week for 9 doses;&#xD;
Cohort 3: ELX-02 1.0 mg/kg or placebo SC twice a week for 9 doses;&#xD;
Cohort 4: ELX-02 2.5 mg/kg or placebo SC twice a week for 9 doses;&#xD;
Cohort 5: ELX-02 up to 2.5 mg/kg (50 mg/mL per injection) or placebo SC twice a week for 9 doses;&#xD;
Cohort 6: ELX-02 2.5 to 5.0 mg/kg or placebo SC twice a week for 9 doses. Optional Cohort&#xD;
Cohort 7: ELX-02 up to 5.0 mg/kg or placebo SC twice a week for 9 doses. Optional Cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters - Plasma AUC0-24</measure>
    <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose</time_frame>
    <description>Day 1 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 to 24 hours post-ose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters- Plasma AUC0-24</measure>
    <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose</time_frame>
    <description>Day 29 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 to 24 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters - Plasma Cmax</measure>
    <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h, post-dose</time_frame>
    <description>Day 1 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 1 to 72 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters - Plasma Cmax</measure>
    <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose</time_frame>
    <description>Day 29 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 29 to 72 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter - Plasma AUC0-inf</measure>
    <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose</time_frame>
    <description>Day 1 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter - Plasma AUC0-inf</measure>
    <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose</time_frame>
    <description>Day 29 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter - Plasma Tmax</measure>
    <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose</time_frame>
    <description>Day 1 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter Plasma - Tmax</measure>
    <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose</time_frame>
    <description>Day 29 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter - Plasma Rac(AUC24h)</measure>
    <time_frame>Day 1 and Day 24 hr</time_frame>
    <description>Accumulation ratio, calculated as AUC24h Day29/AUC24h Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter - Plasma RAC(Cmax)</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>Accumulation ratio, calculated as Cmax Day29/Cmax Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - Ae72h</measure>
    <time_frame>Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
    <description>Day 1 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - Ae72h</measure>
    <time_frame>Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
    <description>Day 29 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetic Parameter - Rmax</measure>
    <time_frame>Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
    <description>Day 1 Maximum rate of urinary extraction (Rmax) of EXL-02 in each collection time interval following the subcutaneous (SC) dose on Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetic Parameter - Rmax</measure>
    <time_frame>Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
    <description>Day 29 Maximum rate of urinary extraction (Rmax) of ELX-02 in each collection time interval following the subcutaneous (SC) dose on Day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - Fe12h Day 1</measure>
    <time_frame>12 hours</time_frame>
    <description>Percent of dose excreted (Fe) in urine on Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - Fe 12h on Day 29</measure>
    <time_frame>12 h on Day 29</time_frame>
    <description>Percent of dose excreted (Fe) in urine on Day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - CLR24h on Day 1</measure>
    <time_frame>24 hours</time_frame>
    <description>Renal clearance on Day 1 (CLR=Ae24h/plasmaAUC24h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacokinetics Parameter - CLR24h</measure>
    <time_frame>24 h</time_frame>
    <description>Renal clearance on Day 29 (CLR=Ae24h/plasmaAUC24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1-29</time_frame>
    <description>TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Genetic Disease</condition>
  <condition>Nonsense Mutation</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ELX-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELX-02</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX-02</intervention_name>
    <description>ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug</description>
    <arm_group_label>ELX-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Comparator Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Subjects must meet all of the following inclusion criteria to be&#xD;
        eligible for enrollment into the study:&#xD;
&#xD;
          1. Be able and willing to provide written Informed Consent indicating that the subject&#xD;
             has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          2. Healthy female subjects and male subjects who, at the time of screening, are between&#xD;
             the ages of 18 and 55 years, inclusive.&#xD;
&#xD;
             Healthy is defined as no clinically relevant abnormalities identified by a detailed&#xD;
             medical history, full physical examination, including blood pressure (BP) and pulse&#xD;
             rate measurement, 12-lead electrocardiogram (ECG), and clinical laboratory tests.&#xD;
&#xD;
          3. Female subjects of non-childbearing potential must meet at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Achieved postmenopausal status, defined as follows: cessation of regular menses&#xD;
                  for at least 12 consecutive months with no alternative pathological or&#xD;
                  physiological cause; post-menopausal status will be confirmed by a serum&#xD;
                  follicle-stimulating hormone level;&#xD;
&#xD;
               -  Have undergone a documented hysterectomy and/or bilateral oophorectomy;&#xD;
&#xD;
               -  Have medically confirmed ovarian failure. All other female subjects (including&#xD;
                  females with tubal ligations) will be considered to be of childbearing potential&#xD;
                  and may be enrolled if they have negative pregnancy tests at screening and&#xD;
                  admission day and agree to use a highly effective method of contraception for 14&#xD;
                  days before first study drug administration and 28 days after last study drug&#xD;
                  administration. Female subjects of childbearing potential must agree to undergo&#xD;
                  repeated pregnancy tests.&#xD;
&#xD;
          4. Male subjects must be willing to use an effective method of contraception. They must&#xD;
             agree to use a condom consistently and correctly, during the course of the study until&#xD;
             28 days after last study drug administration.&#xD;
&#xD;
          5. Not using any prescription medication and dietary supplements within 30 days or 5 half&#xD;
             lives (whichever is longer) prior to the first study drug administration, except for&#xD;
             contraceptives - nor be taking any over-the-counter (OTC) herbal or medicinal&#xD;
             products. As an exception, acetaminophen/paracetamol may be used at doses of ≤2 g/day.&#xD;
&#xD;
          6. Non-smoking and no use of any tobacco or nicotine products (by declaration) for a&#xD;
             period of at least 6 months prior to screening visit.&#xD;
&#xD;
          7. Be on no medication with potential to impair renal function (e.g., non steroidal anti&#xD;
             inflammatory [NSAID]s) or with ototoxic potential (e.g., quinine, salicylates,&#xD;
             aminoglycosides).&#xD;
&#xD;
          8. Normal renal function (glomular filtration rate &gt;60 mL/min) based on creatinine plasma&#xD;
             concentration and the Modification of Diet in Renal Disease (MDRD) equation for&#xD;
             estimated glomular filtration rate. Subjects with lower MDRD clearance can be included&#xD;
             on the condition that they have a normal 24h creatinine clearance (determined by a 24h&#xD;
             urine collection).&#xD;
&#xD;
          9. Negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C virus antibody (HCV Ab) serology tests at screening.&#xD;
&#xD;
         10. No history of alcohol or DOA. Negative urine test for DOA and alcohol breath test at&#xD;
             screening and Day -1.&#xD;
&#xD;
         11. No personal history (or current) or hereditary hearing loss, persistent tinnitus,&#xD;
             persistent vertigo, persistent imbalance and persistent unsteadiness.&#xD;
&#xD;
         12. Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive); and a total body weight &gt;50.0&#xD;
             kg (110 lbs) and &lt;100.0 kg.&#xD;
&#xD;
        Exclusion criteria: Subjects with any of the following characteristics/conditions will not&#xD;
        be included in the study:&#xD;
&#xD;
          1. Subjects who are investigational site staff members directly involved in the conduct&#xD;
             of the study and their family members, site staff members otherwise supervised by the&#xD;
             Investigator, or subjects who are the Sponsor employees directly involved in the&#xD;
             conduct of the study.&#xD;
&#xD;
          2. Concurrent participation or participation in another clinical trial within at least 5&#xD;
             tissue half-lives prior to dosing (calculated from the previous study's last dosing&#xD;
             day). If the previous trial involved agents with delayed effects or prolonged&#xD;
             metabolism, a 12 months interval is required.&#xD;
&#xD;
          3. Evidence or history of clinically relevant hematological, renal, endocrine, pulmonary,&#xD;
             gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic&#xD;
             disease (including drug allergies). This includes any acute or chronic medical or&#xD;
             psychiatric condition or laboratory abnormality that may increase the risk associated&#xD;
             with study participation or investigational drug administration or may interfere with&#xD;
             the interpretation of study results and, in the judgment of the Investigator, would&#xD;
             make the subject inappropriate for entry into this study.&#xD;
&#xD;
          4. Presence of mitochondrial mutations making subject susceptible to aminoglycoside&#xD;
             toxicity.&#xD;
&#xD;
          5. Subjects with any history of ear disease or surgeries, persistent dizziness or&#xD;
             persistent tinnitus.&#xD;
&#xD;
          6. Subjects with any abnormality at screening, that indicates the presence of a&#xD;
             vestibular pathology, conductive hearing loss or balance problem (by an ENT).&#xD;
&#xD;
             Subjects with abnormalities in audiometry results at screening as follows: any&#xD;
             pure-tone threshold &gt;55 dB and/or inter-ear difference in any frequency of &gt;20 dB.&#xD;
&#xD;
             Dizziness Handicap Inventory (DHI)-H score&gt;16. Tinnitus Handicap Inventory (THI)-H&#xD;
             score &gt;14.&#xD;
&#xD;
          7. History of regular alcohol consumption exceeding 14 drinks/week for females or 21&#xD;
             drinks/week for males (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard&#xD;
             liquor) within 6 months of screening.&#xD;
&#xD;
          8. Screening supine BP ≥ 140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic), following at&#xD;
             least 5 min of supine rest. If BP is ≥ 140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic),&#xD;
             the BP should be repeated two more times and the average of the three BP values should&#xD;
             be used to determine the subject's eligibility.&#xD;
&#xD;
          9. Screening supine 12-lead ECG demonstrating QTc &gt;450 msec for men and &gt;470 msec for&#xD;
             women, or a QRS interval &gt;120 msec. If QTc or QRS exceed these limits, the ECG should&#xD;
             be repeated two more times and the average of the three QTc or QRS values should be&#xD;
             used to determine the subject's eligibility.&#xD;
&#xD;
         10. Subjects with ANY abnormalities in clinical laboratory tests at screening, considered&#xD;
             by the study physician as clinically relevant. In particular, subjects with alanine&#xD;
             aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine and total&#xD;
             bilirubin ≥ 1.5 upper limit of normal will be excluded.&#xD;
&#xD;
         11. Pregnant or breastfeeding female subjects.&#xD;
&#xD;
         12. Subjects who donated blood or received blood or plasma derivatives in the three months&#xD;
             preceding study drug administration.&#xD;
&#xD;
         13. Unwilling or unable to comply with all scheduled visits, treatment plan, laboratory&#xD;
             tests and other study procedures and the restrictions described in this protocol.&#xD;
&#xD;
         14. Known relevant allergy to any drug and/or aminoglycosides.&#xD;
&#xD;
         15. Subjects with an inability to communicate well with the Investigators and CPU staff&#xD;
             (e.g., language problem, poor mental development).&#xD;
&#xD;
         16. Subjects with visual impairment or inability to read and comprehend the DHI and THI&#xD;
             scales.&#xD;
&#xD;
         17. Subjects with any acute medical situation (e.g., acute infection) within 48 hours of&#xD;
             study start, which is considered of significance by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS Life Sciences, Clinical Pharmacology Unit</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.eloxxpharma.com</url>
    <description>Eloxx Pharmaceuticals Website</description>
  </link>
  <results_reference>
    <citation>Leubitz A, Vanhoutte F, Hu MY, Porter K, Gordon E, Tencer K, Campbell K, Banks K, Haverty T. A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects. Clin Pharmacol Drug Dev. 2021 Aug;10(8):859-869. doi: 10.1002/cpdd.914. Epub 2021 Jan 19.</citation>
    <PMID>33465285</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>February 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Translational read through</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03309605/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03309605/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects were treated at medical clinics. The first patient was enrolled on 22 November 2017 and the last subject visit occurred on 18 July 2019.</recruitment_details>
      <pre_assignment_details>Nine (9) subjects were to be randomized to receive ELX-02 or placebo at the 2:1 ratio in each cohort. However, only 8 subjects were randomized in Cohort 2. Subjects who received placebo in any of the 7 cohorts were pooled in the All Placebo group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>0.1 mg/kg Concentration 50 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>0.3 mg/kg Concentration 50 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>1.0 mg/kg Concentration 100 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>2.5 mg/kg Concentration 100 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5</title>
          <description>1.0 mg/kg Concentration 50 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6</title>
          <description>2.5 mg/kg Concentration 50 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7</title>
          <description>5.0 mg/kg Concentration 50 mg/mL, twice a week for 9 doses</description>
        </group>
        <group group_id="P8">
          <title>All Placebo</title>
          <description>Placebo, twice a week for 9 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>0.1 mg/kg Concentration 50 mg/mL</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>0.3 mg/kg Concentration 50 mg/mL</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>1.0 mg/kg Concentration 100 mg/mL</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>2.5 mg/kg Concentration 100 mg/mL</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5</title>
          <description>1.0 mg/kg Concentration 50 mg/mL</description>
        </group>
        <group group_id="B6">
          <title>Cohort 6</title>
          <description>2.5 mg/kg Concentration 50 mg/mL</description>
        </group>
        <group group_id="B7">
          <title>Cohort 7</title>
          <description>5.0 mg/kg Concentration 50 mg/mL</description>
        </group>
        <group group_id="B8">
          <title>All Placebo</title>
          <description>0 mg/kg</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="21"/>
            <count group_id="B9" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="12.43"/>
                    <measurement group_id="B2" value="36.0" spread="8.69"/>
                    <measurement group_id="B3" value="37.7" spread="14.51"/>
                    <measurement group_id="B4" value="37.0" spread="11.26"/>
                    <measurement group_id="B5" value="37.8" spread="10.46"/>
                    <measurement group_id="B6" value="44.8" spread="11.14"/>
                    <measurement group_id="B7" value="33.5" spread="7.74"/>
                    <measurement group_id="B8" value="38.9" spread="11.16"/>
                    <measurement group_id="B9" value="38.5" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters - Plasma AUC0-24</title>
        <description>Day 1 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 to 24 hours post-ose</description>
        <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters - Plasma AUC0-24</title>
          <description>Day 1 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 to 24 hours post-ose</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1105.126" spread="15.261"/>
                    <measurement group_id="O2" value="3125.484" spread="13.836"/>
                    <measurement group_id="O3" value="11018.22" spread="12.436"/>
                    <measurement group_id="O4" value="28235.823" spread="16.255"/>
                    <measurement group_id="O5" value="61906.528" spread="20.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters- Plasma AUC0-24</title>
        <description>Day 29 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 to 24 hours post-dose</description>
        <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters- Plasma AUC0-24</title>
          <description>Day 29 Area under the curve (AUC0-24) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 to 24 hours post-dose</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215.098" spread="15.431"/>
                    <measurement group_id="O2" value="3109.978" spread="16.601"/>
                    <measurement group_id="O3" value="10847.306" spread="14.098"/>
                    <measurement group_id="O4" value="29651.700" spread="23.223"/>
                    <measurement group_id="O5" value="54749.370" spread="13.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters - Plasma Cmax</title>
        <description>Day 1 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 1 to 72 hours post-dose</description>
        <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h, post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters - Plasma Cmax</title>
          <description>Day 1 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 1 to 72 hours post-dose</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.710" spread="21.060"/>
                    <measurement group_id="O2" value="1003.266" spread="5.766"/>
                    <measurement group_id="O3" value="2880.233" spread="11.647"/>
                    <measurement group_id="O4" value="7721.256" spread="6.387"/>
                    <measurement group_id="O5" value="15912.090" spread="17.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters - Plasma Cmax</title>
        <description>Day 29 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 29 to 72 hours post-dose</description>
        <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters - Plasma Cmax</title>
          <description>Day 29 Peak Plasma Concentration (Cmax) of ELX-02 following the subcutaneous (SC) dose on Day 29 to 72 hours post-dose</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.779" spread="12.021"/>
                    <measurement group_id="O2" value="961.448" spread="7.460"/>
                    <measurement group_id="O3" value="2806.966" spread="16.403"/>
                    <measurement group_id="O4" value="7852.172" spread="12.342"/>
                    <measurement group_id="O5" value="15435.789" spread="13.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter - Plasma AUC0-inf</title>
        <description>Day 1 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 extrapolated to infinity</description>
        <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Plasma AUC0-inf</title>
          <description>Day 1 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 1 extrapolated to infinity</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1107.272" spread="15.345"/>
                    <measurement group_id="O2" value="3127.964" spread="13.898"/>
                    <measurement group_id="O3" value="11036.305" spread="12.631"/>
                    <measurement group_id="O4" value="28335.680" spread="16.468"/>
                    <measurement group_id="O5" value="62142.763" spread="20.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter - Plasma AUC0-inf</title>
        <description>Day 29 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 extrapolated to infinity</description>
        <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Plasma AUC0-inf</title>
          <description>Day 29 Area under the curve (AUC0-inf) of ELX-02 plasma concentration following the subcutaneous (SC) dose on Day 29 extrapolated to infinity</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1216.448" spread="15.428"/>
                    <measurement group_id="O2" value="3114.486" spread="16.704"/>
                    <measurement group_id="O3" value="10862.927" spread="14.239"/>
                    <measurement group_id="O4" value="29778.143" spread="23.469"/>
                    <measurement group_id="O5" value="54933.538" spread="13.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter - Plasma Tmax</title>
        <description>Day 1 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 1</description>
        <time_frame>Day 1: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Plasma Tmax</title>
          <description>Day 1 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 1</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O5" value="0.86" lower_limit="0.73" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter Plasma - Tmax</title>
        <description>Day 29 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 29</description>
        <time_frame>Day 29: pre-dose, 15 min, 30 min, 45 min, 1h, 3h, 6h, 12h, 24h, 36h, 48h, 72h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter Plasma - Tmax</title>
          <description>Day 29 Time to maximum concentration (Tmax) of ELX-02 plasma concentrations following the subcutaneous (SC) dose on Day 29</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.75" upper_limit="1.00"/>
                    <measurement group_id="O5" value="0.98" lower_limit="0.73" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter - Plasma Rac(AUC24h)</title>
        <description>Accumulation ratio, calculated as AUC24h Day29/AUC24h Day 1</description>
        <time_frame>Day 1 and Day 24 hr</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Plasma Rac(AUC24h)</title>
          <description>Accumulation ratio, calculated as AUC24h Day29/AUC24h Day 1</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.093" spread="7.497"/>
                    <measurement group_id="O2" value="0.995" spread="6.622"/>
                    <measurement group_id="O3" value="0.984" spread="7.892"/>
                    <measurement group_id="O4" value="1.056" spread="14.161"/>
                    <measurement group_id="O5" value="0.911" spread="13.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter - Plasma RAC(Cmax)</title>
        <description>Accumulation ratio, calculated as Cmax Day29/Cmax Day 1</description>
        <time_frame>Day 1 and Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Plasma RAC(Cmax)</title>
          <description>Accumulation ratio, calculated as Cmax Day29/Cmax Day 1</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.217" spread="15.278"/>
                    <measurement group_id="O2" value="0.958" spread="7.429"/>
                    <measurement group_id="O3" value="0.976" spread="12.401"/>
                    <measurement group_id="O4" value="1.018" spread="15.413"/>
                    <measurement group_id="O5" value="0.941" spread="1.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - Ae72h</title>
        <description>Day 1 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 1</description>
        <time_frame>Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - Ae72h</title>
          <description>Day 1 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 1</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.702" spread="16.721"/>
                    <measurement group_id="O2" value="15.177" spread="8.524"/>
                    <measurement group_id="O3" value="58.270" spread="20.046"/>
                    <measurement group_id="O4" value="160.665" spread="11.622"/>
                    <measurement group_id="O5" value="332.467" spread="18.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - Ae72h</title>
        <description>Day 29 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 29</description>
        <time_frame>Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - Ae72h</title>
          <description>Day 29 Cumulative amount of unchanged drug excreted into urine (Ae72h) of ELX-02 following the subcutaneous (SC) dose on Day 29</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.331" spread="28.505"/>
                    <measurement group_id="O2" value="15.021" spread="9.189"/>
                    <measurement group_id="O3" value="66.354" spread="15.505"/>
                    <measurement group_id="O4" value="162.609" spread="12.742"/>
                    <measurement group_id="O5" value="399.302" spread="14.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetic Parameter - Rmax</title>
        <description>Day 1 Maximum rate of urinary extraction (Rmax) of EXL-02 in each collection time interval following the subcutaneous (SC) dose on Day 1</description>
        <time_frame>Day 1: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetic Parameter - Rmax</title>
          <description>Day 1 Maximum rate of urinary extraction (Rmax) of EXL-02 in each collection time interval following the subcutaneous (SC) dose on Day 1</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>mg/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.846" spread="30.561"/>
                    <measurement group_id="O2" value="4.759" spread="6.706"/>
                    <measurement group_id="O3" value="16.132" spread="15.540"/>
                    <measurement group_id="O4" value="41.587" spread="21.200"/>
                    <measurement group_id="O5" value="69.304" spread="13.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetic Parameter - Rmax</title>
        <description>Day 29 Maximum rate of urinary extraction (Rmax) of ELX-02 in each collection time interval following the subcutaneous (SC) dose on Day 29</description>
        <time_frame>Day 29: pre-dose and during 0-12h, 12-24h, 24-48h, and 48-72h post-dose</time_frame>
        <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetic Parameter - Rmax</title>
          <description>Day 29 Maximum rate of urinary extraction (Rmax) of ELX-02 in each collection time interval following the subcutaneous (SC) dose on Day 29</description>
          <population>Plasma ELX-02 exposure was generally similar following SC administration of either a 50 or 100 mg/mL final diluted injection solution strength, indicating no formulation-related differences in PK, therefore the results from Cohorts 3 and 5, and Cohorts 4 and 6 were combined.</population>
          <units>mg/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.950" spread="37.938"/>
                    <measurement group_id="O2" value="5.028" spread="15.875"/>
                    <measurement group_id="O3" value="18.327" spread="23.862"/>
                    <measurement group_id="O4" value="40.607" spread="18.389"/>
                    <measurement group_id="O5" value="89.796" spread="14.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - Fe12h Day 1</title>
        <description>Percent of dose excreted (Fe) in urine on Day 1</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - Fe12h Day 1</title>
          <description>Percent of dose excreted (Fe) in urine on Day 1</description>
          <units>percentage of drug excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.572" spread="10.030"/>
                    <measurement group_id="O2" value="79.440" spread="6.178"/>
                    <measurement group_id="O3" value="76.028" spread="17.403"/>
                    <measurement group_id="O4" value="89.639" spread="9.227"/>
                    <measurement group_id="O5" value="83.362" spread="5.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - Fe 12h on Day 29</title>
        <description>Percent of dose excreted (Fe) in urine on Day 29</description>
        <time_frame>12 h on Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - Fe 12h on Day 29</title>
          <description>Percent of dose excreted (Fe) in urine on Day 29</description>
          <units>percentage of drug excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.095" spread="14.874"/>
                    <measurement group_id="O2" value="78.398" spread="3.615"/>
                    <measurement group_id="O3" value="88.130" spread="15.218"/>
                    <measurement group_id="O4" value="88.914" spread="4.157"/>
                    <measurement group_id="O5" value="94.219" spread="7.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - CLR24h on Day 1</title>
        <description>Renal clearance on Day 1 (CLR=Ae24h/plasmaAUC24h)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - CLR24h on Day 1</title>
          <description>Renal clearance on Day 1 (CLR=Ae24h/plasmaAUC24h)</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.871" spread="22.645"/>
                    <measurement group_id="O2" value="4.823" spread="9.834"/>
                    <measurement group_id="O3" value="5.251" spread="19.135"/>
                    <measurement group_id="O4" value="5.653" spread="22.959"/>
                    <measurement group_id="O5" value="5.331" spread="16.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Pharmacokinetics Parameter - CLR24h</title>
        <description>Renal clearance on Day 29 (CLR=Ae24h/plasmaAUC24h)</description>
        <time_frame>24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics Parameter - CLR24h</title>
          <description>Renal clearance on Day 29 (CLR=Ae24h/plasmaAUC24h)</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.152" spread="29.234"/>
                    <measurement group_id="O2" value="4.784" spread="10.828"/>
                    <measurement group_id="O3" value="6.068" spread="17.200"/>
                    <measurement group_id="O4" value="5.435" spread="28.521"/>
                    <measurement group_id="O5" value="7.239" spread="7.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment</description>
        <time_frame>Day 1-29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>0.1 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>0.3 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 and Cohort 5</title>
            <description>1.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4 and Cohort 6</title>
            <description>2.5 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7</title>
            <description>5.0 mg/kg, twice a week for 9 doses</description>
          </group>
          <group group_id="O6">
            <title>All Placebo</title>
            <description>Placebo, twice a week for 9 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>TEAEs are undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the study treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of signing the consent form until Day 36</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>0.1 mg/kg, twice a week for 9 doses</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>0.3 mg/kg, twice a week for 9 doses</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 and Cohort 5</title>
          <description>1.0 mg/kg, twice a week for 9 doses</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4 and Cohort 6</title>
          <description>2.5 mg/kg, twice a week for 9 doses</description>
        </group>
        <group group_id="E5">
          <title>Cohort 7</title>
          <description>5.0 mg/kg, twice a week for 9 doses</description>
        </group>
        <group group_id="E6">
          <title>All Placebo</title>
          <description>Placebo, twice a week for 9 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="23" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" events="59" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E5" events="66" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vessel puncture site hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Audiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Director Clinical Trials</name_or_title>
      <organization>Eloxx Pharmaceuticals</organization>
      <phone>1-781-577-5300</phone>
      <email>CTI@eloxxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

